HEART RATE AND BLOOD PRESSURE                        
 
Stimulant medication is recognised to result in a small increase in heart rate. In rare occasions, an increase of up to 50 beats per minute has been observed. However, there is a lack of long-term data on appropriate control subjects in studies investigating the impact of methylphenidate on heart rate. Methylphenidate, like other stimulant drugs, is also well known to have small, short term effects on blood pressure. A more relevant measure of risk, however, would be whether increases resulted in children entering the category of hypertension (high blood pressure), and if so how many children/young people are affected in this way. ADDUCE will address these issues in children through the current study.
 
SUDDEN DEATH     
 
Sudden cardiac death has been reported in children taking methylphenidate. However, whether methylphenidate was the cause remains uncertain. It is not easy to determine whether the observed rate of sudden death in children with ADHD is higher or lower than that observed in the general population. The physical and mental health comorbidities associated with a diagnosis may themselves increase the risk of death from other causes. As sudden death in children is so rare, very large studies would be required to adequately examine this question and they will not be addressed by the current study.

News

The fifth ADDUCE Newsletter is now available!

Here, you can read about the finalisation of the project,

the European Medicines Agency and General Assembly meetings

and the dissemination of the results!

The fourth ADDUCE Newsletter is available!
 
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study

- the long-term cardiascular effects of methylphenidate use
 
Also, you can read about the future plans of the project!

More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before! 

 

Did you participate in the ADDUCE studies and are you curious about the latest news on the project?

Here you can find some information!

News for children, April 2015

News for adolescents, April 2015

News for parents, April 2015

The third ADDUCE Newsletter is available!
 

Read more about the ADDUCE studies:

- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
off studies
- the long-term cardiovascular effects of methylphenidate use: study design and participation
 

and much more in the ADDUCE Newsletter 3, March 2015

 

The second ADDUCE Newsletter is available!
Read more about the 2 main ADDUCE studies:

  • WP3: prospective open-label methylphenidate
    pharmacovigilance study
  • WP8: long-term cardiovascular effects of methylphenidate use

and much more in the ADDUCE Newsletter 2, February 2013

Events

16 - 19 OCTOBER 2016:

4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care

17 & 18 APRIL 2016:

ADDUCE Consortium meeting, London - UK

28 - 31 MAY 2015:

5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland

20 & 21 APRIL 2015:

ADDUCE Consortium meeting, Salina - Italy

21 - 24 MAY 2014:

3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders

19 & 20 MAY 2014:

ADDUCE Consortium meeting, Istanbul - Turkey

3 - 6 OCTOBER 2013:

23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders

6 - 9 JUNE 2013:            

4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy

4 & 5 JUNE 2013:

ADDUCE Consortium meeting, Milan - Italy

 6 & 7 JUNE 2012:            

ADDUCE Consortium meeting, Cagliari - Italy

23 MAY 2012:

2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain